11filings we hold
8topics disclosed
Chemicals and pharmaceuticalsindustry
MAbased in
Across 11 filings we hold,
Korro Bio, Inc. has written down 8 of the topics we track. That places it 413 of 755 companies we hold in chemicals and pharmaceuticals, by how much we have collected.
Korro Bio, Inc. has written 8 of our tracked topics into its filings. What it disclosed is public. What that now obligates is not, and it is 682 controls.From SEC filings and our framework corpus
What it discloses
Tracked topics appearing in this company's filings, most frequent first. Each opens
the topic, where you can see who else files it and what it obligates.
What this obligates
Every instrument below governs something Korro Bio, Inc. has written into a filing. This maps to obligations within those frameworks. It is not a finding that the company has failed any of them, and nothing here establishes noncompliance.
10 frameworks, 682 controls between them, deduplicated across topics.
And what those same controls reach into
The controls behind those frameworks also appear in the instruments below, which suggests increased attention to them follows from the same work rather than from a separate programme.
ISO 27701:2019724
ISO 27002:2022622
ISO 22301:2019404
NIS2 Directive201
PCI DSS 4.0182
COBIT 2019148
ISO/IEC 38500:2024142
ISO 22000:201846
Tell me when Korro Bio, Inc. files something new
One email when there is a new SEC filing, naming what it is and what our corpus says it puts in scope. Nothing else, and one click to stop.
When it filed
Filings we hold, by year. Hover a bar for the count. Peak 4 in 2026.
Recent filings
| Filed | Form | Item | |
|---|
| 2026-08-06 | 10-Q | | filing |
| 2026-05-07 | 10-Q | | filing |
| 2026-03-12 | 10-K | | filing |
| 2026-03-09 | 8-K | Entry into a material agreement, Results of operations, the earnings release, Item 3.02 | filing |
| 2024-04-18 | 8-K | Entry into a material agreement, Item 3.02, Regulation FD disclosure | filing |
| 2023-11-06 | 8-K | Entry into a material agreement, Completion of an acquisition, Results of operations, the earnings release | filing |
| 2023-07-14 | 8-K | Entry into a material agreement, Item 5.01, Director or officer departure | filing |
| 2023-05-12 | 10-Q | | filing |
| 2021-12-10 | 8-K | Entry into a material agreement, Financial statements and exhibits | filing |
| 2020-09-25 | 8-K | Director or officer departure, Item 5.03, Financial statements and exhibits | filing |
| 2020-07-21 | 8-K | Entry into a material agreement, Item 3.02, Financial statements and exhibits | filing |
Others in chemicals and pharmaceuticals
The companies we hold most on in the same industry classification. Each opens side by
side with this one.
What this page is
Every row comes from SEC full-text search over this company's filings, matched against the
compliance and risk phrases we track. It is a record of what the company itself wrote down, in
documents it is legally accountable for. It is not an assessment of the company, a rating, or
a claim about how well it manages anything.
A phrase appearing in a filing frequently means the risk section
mentions it, not that an event occurred. Where an item number indicates an actual event, the
Item column says so.
All of
chemicals and pharmaceuticals · All companies ·
Today's edition